- Patient outcomes were defined by protocol (n=107) or for-cause (n=44) kidney biopsy.
- Median time to biopsy and Tutivia risk score was 57 days, and a high risk score predicting acute rejection as early as 6 days post-transplant.
80% of clinically indicated biopsies were performed within the first sixty days.
- 69% of these had acute rejection by histopathology.
- 83% of early biopsies with pathologic acute rejection had a high Tutivia risk score.
Director of Scientific Communications
The data to inform, the drive to earn trust.
Verici Dx partners with clinicians and their patients to offer a platform of single and related tests to improve patient care over the course of their transplant journey.
Driven by curiosity. Delivered by science.
The drive to innovate and develop the suite of Verici Dx diagnostic products is spearheaded by our experienced molecular scientists and highly qualified bioinformaticians alongside AI machine learning technology...
driven by curiosity.
delivered by science.
Personalized Testing for Patient Care
Commitment to the Transplant Community
VericiDx supports the Living Donor Protection Act currently before congress. We believe that living donors deserve time off from work without penalty, should not be able to be fired from their jobs after surgery due to their donation, and should have the ability to get life insurance, disability, and long-term care insurance without discrimination by being a living donor. We will be reaching out to our congressional representatives to support this bill.
American Society for Transplantation is actively involved in guiding our leaders to support and protect living donors.
Learn more about the Living Donor Protection Act of 2023 on the AST site.
- Tutivia utilizes a proprietary RNA gene expression signature with an algorithm to generate a risk score for acute rejection (AR).
- A patient with a Tutivia high-risk score is nearly 6 times more likely to be experiencing an acute rejection compared to a patient with a low-risk score.
- Tutivia can differentiate acute rejection from BK nephropathy; patients with a positive SV-40 stain on kidney biopsy were highly correlated to a very low Tutivia risk score.
- The RNA signature is derived from dynamic biological systems involved in the inflammatory response, the interplay of immune cells involved in transplant rejection, and genes involved in cell repair and metabolism in the kidney.
- The Tutivia signature algorithm was derived utilizing machine learning techniques to identify and estimate an individualized patient’s risk of AR.
- Tutivia was validated in a prospective, international, multicenter, blinded observational study with a broadly diverse patient population and a full range of kidney donors.
- The study outcomes evaluated patients for the full spectrum of acute rejection, including borderline, utilizing BANFF 2019 criteria.
- Tutivia testing is performed in the fully accredited Verici Dx clinical laboratory under rigorous quality assurance program.